Standardized microfluidic assessment of red blood cell–mediated microcapillary occlusion: Association with clinical phenotype and hydroxyurea responsiveness in sickle cell disease
Objectives We present a standardized in vitro microfluidic assay and Occlusion Index (OI) for the assessment of red blood cell (RBC)–mediated microcapillary occlusion and its clinical associations in sickle cell disease (SCD). Methods Red blood cell mediated microcapillary occlusion represented by O...
Saved in:
Published in | Microcirculation (New York, N.Y. 1994) Vol. 28; no. 2; pp. e12662 - n/a |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.02.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objectives
We present a standardized in vitro microfluidic assay and Occlusion Index (OI) for the assessment of red blood cell (RBC)–mediated microcapillary occlusion and its clinical associations in sickle cell disease (SCD).
Methods
Red blood cell mediated microcapillary occlusion represented by OI and its clinical associations were assessed for seven subjects with hemoglobin‐SC disease (HbSC), 18 subjects with homozygous SCD (HbSS), and five control individuals (HbAA).
Results
We identified two sub‐populations with HbSS based on the OI distribution. HbSS subjects with relatively higher OIs had significantly lower hemoglobin levels, lower fetal hemoglobin (HbF) levels, and lower mean corpuscular volume (MCV), but significantly higher serum lactate dehydrogenase levels and absolute reticulocyte counts, compared to subjects with HbSS and lower OIs. HbSS subjects who had relatively higher OIs were more likely to have had a concomitant diagnosis of intrapulmonary shunting (IPS). Further, lower OI associated with hydroxyurea (HU) responsiveness in subjects with HbSS, as evidenced by significantly elevated HbF levels and MCV.
Conclusions
We demonstrated that RBC‐mediated microcapillary occlusion and OI associated with subject clinical phenotype and HU responsiveness in SCD. The presented standardized microfluidic assay may be useful for evaluating clinical phenotype and assessing therapeutic outcomes in SCD, including emerging targeted and curative treatments that aim to improve RBC deformability and microcirculatory health. |
---|---|
Bibliography: | National Science Foundation Award: 1552782; National Heart, Lung, and Blood Institute Awards: R01HL133574, OT2HL152643, U01HL117659, and T32HL134622. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 AUTHOR CONTRIBUTIONS Y.M. and U.A.G. conceived the project. Y.M. performed the experiments, acquired and analyzed the data. Y.M., E.K., R.A., J.A.L. and U.A.G. discussed and interpreted the data. Y.M. prepared the figures and table, and wrote the manuscript. Y.M., E.K., R.A., J.A.L. and U.A.G. edited the manuscript. J.A.L provided the patient samples. A.B. collected the patient clinical information. |
ISSN: | 1073-9688 1549-8719 1549-8719 |
DOI: | 10.1111/micc.12662 |